Treats edema. ANDA 211232, held by Sciegen Pharms. Ethacrynic Acid.
As of Nov 16, 2026, ANDA 211232 (Ethacrynic Acid), held by Sciegen Pharms, was first approved by FDA on Aug 27, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ethacrynic Acid Tablets, USP are indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ethacrynic Acid25MG · tablet;oral | Ethacrynic Acid | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters